The Arrowhead Story
At Arrowhead, we do things differently. Everything we do is aimed at making someone’s life better by harnessing our best scientific efforts. We consistently explore new ways of rapidly advancing drugs from discovery to the clinic, because we know every day matters to the patients we serve.
The RNAi Difference
Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable suppression of target genes. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
We are pioneering the use of RNAi to target genes and treat disease pathways that were previously thought to be “undruggable”. Unlike other RNAi companies, we are agnostic to the target tissue and are successfully advancing important medicines across a broad range of disease areas including of cardiometabolic, pulmonary, liver, and other diseases.
20 in 25
Our pipeline is always growing, and we’re always looking for new targets that can be addressed with RNAi technology.
As we look to the future, we continue to rely on the 10 fundamental Arrowhead Values that are the bedrock of our success, and we’ve embraced the bold goal of having 20 individual drugs, either partnered or wholly owned, in a clinical trial or on the market in 2025.
Our core values, a set of 10 guiding beliefs, drive us every day. They fuel our research and inform our actions in every way.
Everything we do is aimed at making someone’s life better.
We seek out and value diversity of thought, experience, and perspective, and we want our workforce to reflect the patients we serve.
Every day we can save in development is one day earlier a patient has access to our medicines.
We think beyond our individual roles and beyond Arrowhead’s current capabilities.
We are all important and valuable. We treat each other, our patients, and those outside Arrowhead with respect.
Innovation springs from questioning. We always ask why.
Seeking and propagating the truth is the cornerstone of what we do. It may not always be comfortable, but it is always critical.
The ability to change course rapidly is critical for innovation.
Creativity and speed die by committee. Extraordinary people who are empowered to make decisions will do extraordinary things.
There will always be failure. We remember this, particularly in success.
Areas of Focus
Our commitment to innovating for patients spans a number of therapeutic areas and diseases.
Cardiometabolic diseases impact a large number of people in the US and are caused by interrelated risk factors including hypertension, elevated blood sugar, dyslipidemia, abdominal obesity and elevated triglycerides.
We’re pursuing more treatment options for pulmonary conditions such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and related inflammatory and muco-obstructive pulmonary diseases.
Hepatitis B, Alpha-1 liver disease, and non-alcoholic steatohepatitis (NASH) are just a few of the liver diseases we’re addressing through ground-breaking research and developments.
As we continue to grow our pipeline for neuromuscular conditions, we’re uncovering new ways to improve treatment options with innovative science.
There is always more work to be done. We’re pursuing more medicines outside our areas of focus, so we can continue to bring people hope with life-changing treatments.
Meet the dedicated group of experts that shape Arrowhead every day.
Learn about the mission and vision that’s informed our purpose as a company.
Careers at Arrowhead
Become part of the team who is leading the market through scientific innovation.